The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Using Sacituzumab Govitecan and Other ADCs in Urothelial Cancers

Arlene O. Siefker-Radtke, MD
Published Online:8:38 PM, Tue March 5, 2019


Arlene O. Siefker-Radtke, MD, professor, department of genitourinary medical oncology, division of cancer medicine, The University of Texas MD Anderson Cancer Center, discusses the data seen with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) that targets TROP-2, which is expressed frequently in urothelial cancer cells.

Response rates were around 30% with this agent, but it was associated with toxicites, says Siefker-Radtke. However, toxicities are common with other ADCs, such as enfortumab vedotin, which has a higher rate of neutropenia and neutropenic fevers.

Siefker-Radtke concludes that ADCs provide an additional option for these patients with urothelial cancers to have better outcomes.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.